Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors

Inclusion Criteria:

* Histologically or cytologically confirmed solid tumor which has failed standard therapies (surgery, radiotherapy, endocrine therapy, chemotherapy) or for which effective therapy is not available
* At least 18 years of age
* Hematology: Absolute neutrophil count (ANC) \> 1500 cells/mm3, platelet count \> 100,000 cells/mm3 and hemoglobin \>= 9 gm/L
* Hepatic: Bilirubin \< 1.5 X upper limit of normal (ULN); alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \< 2.5 X ULN. Patients with known liver metastases or liver neoplasms: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \< 5.0 X ULN.
* Renal: Serum creatinine levels \< 2.0 mg/dL or creatinine clearance \> 60 mL/min
* Coagulation: international normalized ratio (INR) \< 1.5 times normal
* Adrenal: Normal plasma cortisol and adrenocorticotropic hormone (ACTH) levels
* Normal electrocardiogram (ECG) with QTc \<= 450 msec for men and \<= 470 msec for women
* Estimated life expectancy of at least 3 months as determined by the Investigator
* Eastern Cooperative Oncology Group (ECOG) performance status \<= 2
* Male and female patients of childbearing potential must practice effective double-barrier contraception during the study and continue contraception for 3 months after their last dose of study drug. Male patients must agree to not have intercourse with pregnant or nursing women during the study and for 3 months after their last dose of study drug, unless using double-barrier contraception. The only exceptions to double-barrier contraception are: Patient or partner is surgically sterile,female patient is postmenopausal for at least 1 year before screening or patient abstains from sexual intercourse, at the discretion of the Investigator

Exclusion Criteria:

* Pregnant or nursing women, women of child-bearing age not using reliable means of contraception.
* Radiotherapy or chemotherapy within the previous 28 days. Recovery to Grade 1 or less from chemotherapy-induced toxic effect, except alopecia, is required.
* Participation in any investigational drug study within 28 days prior to CNF2024 administration
* Active infection requiring intravenous antibiotic treatment
* Patients with second malignancy requiring active treatment (except hormonal therapy)
* Concurrent severe or uncontrolled medical disease (i.e., systemic infection, diabetes, hypertension, coronary artery disease, congestive heart failure)
* Active symptomatic fungal, bacterial and/or viral infection including active HIV or viral (A, B or C) hepatitis
* Problems with swallowing or malabsorption
* Chronic diarrhea (excess of 2-3 stools/day above normal frequency)
* Gastrointestinal diseases including gastritis, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis
* Major surgery of the stomach or small intestine
* Adrenal dysfunction \> Grade 2
* Patients with diabetes (your doctor will discuss if you are eligible for this study)